Introduction of Long-Lasting Jornay PM©1 (Methylphenidate HCl) for ADHD - cited by Sierros Christos

By: Cited by Sierros Christos
 
 
Spread the Word
Listed Under

Tag:
* Adhd

Industry:
* Medical

Location:
* New York City - New York - US

NEW YORK - June 20, 2019 - PRLog -- Ironshore is launching Jornay PM (Methylphenidate HCl) extended-effect capsules. The medication is a central nervous system stimulant which has already been approved by the Food & Drug Administration for the treatment of ADHD in patients 6 years or older.

According to the manufacturer, Jornay PM is the first and sole ADHD stimulant medicine which is administered in the evening and helps improve and control symptoms throughout the day

The stimulant drug's evening administration is made possible by Ironshore's novel Delexis drug delivery platform. Delexis consists of 2 functional film coatings which act synergistically to achieve a special pharmaco-kinetic profile. The first layer delays the initial release of drug for up to 10 hours while the second layer helps to control the rate of release of the active pharmaceutical ingredient throughout the day.

About Methylphenidate

Methylphenidate is a stimulant medication used for the treatment of attention deficit hyperactivity disorder (ADHD) and narcolepsy. It is a first-line drug for ADHD. It can be taken by mouth or it can be applied to the skin. Different formulations have different durations of effect.

Common side effects include weight loss, anxiety, and trouble sleeping. More serious side effects may include allergic reactions, prolonged erections, abuse, heart problems, and psychosis.  Methylphenidate is hypothesized to work by improving the action of catecholamines in the brain. It does so by blocking dopamine and norepinephrine re-uptake by neurons. Methylphenidate is a central nervous system (CNS) stimulant of the piperidine and phenethylamine classes.

Methylphenidate was first manufactured in 1944 and was eventually approved for medical use in the US in 1955. It was originally sold by CIBA (currently Novartis Corporation). In 2013 almost 2.4 billion doses of methylphenidate were prescribed worldwide. Approximately 80% of this was taken by people in the US, as its 47th most prescribed drug. It is currently also available in a generic formulation In the US.

Uses

Methylphenidate is mostly used for treating narcolepsy and ADHD.

Attention deficit hyperactivity disorder (ADHD)

Methylphenidate is used for treating attention deficit hyperactivity disorder.  The addition of behavioral modification therapy can have additional synergistic benefits on treatment outcome.

The short-term benefits and cost effectiveness of methylphenidate are well researched.  A number of studies have established the safety and effectiveness of the stimulant medications for individuals with ADHD over a long period of time.

About 70% of patients who are administered these stimulant medications realize improvements in their ADHD symptoms. Children with ADHD who use these stimulants usually have better relationships with peers and family members, usually have improved performance in school, are less distracted and impulsive, and have longer attention spans. People with ADHD have an elevated risk of substance use disorders, and stimulants reduce this risk. Methylphenidate is not approved for children under six years of age. Immediate release methylphenidate is used daily along with the extended release version to achieve full-day symptom control.

Narcolepsy

Narcolepsy, a chronic sleep disorder characterized by overwhelming daytime drowsiness and uncontrollable sleep, is treated mainly with the use of stimulants. Methylphenidate has been proven effective in increasing wakefulness, vigilance, and performance. It improves measures of somnolence on standardized tests, such as the Multiple Sleep Latency Test (MSLT).

Other medical uses

Methylphenidate can be prescribed for off-label use in treatment-resistant bipolar disorder and major depressive disorder cases. It can also improve depression in patients with stroke, cancer, and HIV-positive diagnoses. In terminal cancer patients, methylphenidate can be used to fight opioid-induced somnolence, to boost the analgesic effects of opioids, to treat depression, and to increase cognitive function.  However, the use of stimulants like methylphenidate in treatment-resistant depression cases has been rather controversial.

1 Jornay PM® is a registered trademark of Ironshore Pharmaceuticals Inc.

Cited by Sierros Christos (https://www.flickr.com/photos/christossierros)
End
Email:***@gmail.com Email Verified
Tags:Adhd
Industry:Medical
Location:New York City - New York - United States
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse
Page Updated Last on: Jun 25, 2019
Sierros Christos News
Trending
Most Viewed
Daily News



Like PRLog?
9K2K1K
Click to Share